Brief: Tracon Pharmaceuticals Reports Regulatory Approval Of Envafolimab In China
29/11/2021 13:34
Nov 29 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS REPORTS REGULATORY APPROVAL OF
ENVAFOLIMAB IN CHINA
* TRACON PHARMACEUTICALS - CO'S U.S. TRIAL FOR ENVAFOLIMAB
IN
UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND MYXOFIBROSARCOMA
CONTINUES TO ADVANCE AS PLANNED
Source text for Eikon: ID:nGNX26SJJP
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants